A Case of an Invasive Lobular Carcinoma with Extracellular Mucin: Radio-Pathological Correlation

A case of 77-year-old female with an invasive lobular carcinoma with extracellular mucin is presented. She felt palpable mass in her left breast. Then, she came to our hospital for further examination. Mammography of right in full view revealed architectural distortion in left upper portion. And ultrasonography demonstrated low-echoic mass about 2 cm in diameter and invasion of the fat tissue was observed. Hence, malignancy was suspected and magnetic resonance imaging (MRI) was performed. MRI findings showed irregular shaped and margined mass with small T2-high-signal intensity. These findings suggested invasive carcinoma with mucin. Because the cancer lesion was not large, partial mastectomy was performed. Interestingly, pathological diagnosis was invasive lobular carcinoma with extracellular mucin. Extracellular mucinous lesion was concordant with small T2-high-signal intensity. This type of carcinoma was previously reported only in three cases, and rare but important, because the treatment and prognosis might change by histological subtypes. We suggest one of the MRI special features of our case is not only irregular shaped and margined mass but also small T2-high-signal intensity. These MR findings might be one of the valuable findings for the diagnosis and differentiation between this type of carcinoma from other tumors

DEVELOPMENT OF AUTOIMMUNE THROMBOCYTOPENIA AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL SUPPORT FOR METASTATIC BREAST CANCER

Autoimmune thrombocytopenia (AT) occurs after not only allogeneic but also autologous SCT following high-dose myeloablative chemotherapy against malignant tumors. A 50-year-old woman was diagnosed with metastatic breast cancer (MBC) and received myeloablative chemotherapy followed by autologous peripheral blood stem cell transplantation. Purpura developed on day +40 after transplantation, and a diagnosis of AT was made based on her bone marrow picture and elevation of serum PA-IgG level. Her thrombocytopenia was refractory to treatment with high-dose intravenous immune globulin (IVIG) and steroids. Although her platelet count recovered to within the normal range after splenectomy, 14 months after receiving SCT she died of disseminated intravascular coagulation syndrome caused by progression of cancer metastasis. There have been 10 reported cases of AT developing after high-dose myeloablative chemotherapy against malignant tumors followed by autologous SCT. We suggest that the thrombocytopenia after engraftment was caused by activation of dormant auto-immunity, which our patient potentially had, in conjunction with an insufficient quantity and quality of suppressor T-cells before complete reconstruction of the immune system after myeloablative conditioning. The clinical course of our patient was specific and different from previously reported cases since a splenectomy was necessary due to her thrombocytopenia being refractory to both steroid and IVIG therapy

Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast

Objectives: The aim of this study was to use immunohistochemistry to differentiate solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia (IPUDH). Three types of high-molecular-weight cytokeratins (CKs) – CK5/6, CK14, and CK34betaE12 – were targeted. Methods: We studied 17 patients with solid papillary carcinoma in situ and 18 patients with IPUDH diagnosed by at least two pathologists. Immunohistochemical analyses used antibodies to CK5/6, CK14, and CK34betaE12 to make the differential diagnosis of solid papillary carcinoma in situ versus IPUDH. Immunohistochemical staining was scored as 0–5 using Allred score. Results: Immunohistochemistry with CK5/6 and CK14 antibodies produced scores of 0–3 in all patients with solid papillary carcinoma in situ and 2–5 in all patients with IPUDH. Immunohistochemical staining with CK34betaE12 antibody produced scores of 1–3 in all patients with solid papillary carcinoma and 3–5 in all patients with IPUDH. In tissues from patients with IPUDH, significantly more cells were stained with CK34betaE12 than CK5/6 ( p  < 0.05) or CK14 ( p  < 0.05). Conclusion: The immunoreactivity of CK5/6, CK14, and CK34betaE12 antibodies was useful to differentiate solid papillary carcinoma in situ from IPUDH. CK34betaE12 is especially useful for distinguishing solid papillary carcinoma from IPUDH

Clinicopathological Significance of TARBP2, APP, and ZNF395 in Breast Cancer

The double-stranded RNA-binding protein TARBP2 has been suggested to act as an upstream regulator of breast cancer metastasis by destabilizing transcripts of the possible metastasis suppressors amyloid precursor protein (APP) and ZNF395. We examined this hypothesis by immunostaining of TARBP2, APP, and ZNF395 in 200 breast cancer specimens using tissue microarrays and analyzed the relationships between expression levels and clinicopathological parameters and prognosis. Increased TARBP2 overexpression was associated with shorter overall survival and disease-free survival, and increased but not reduced APP expression correlated with lower overall survival and disease-free survival. ZNF395 expression levels had no prognostic value, but reduced expression correlated with reduced lymph node metastasis. There was no significant relationship between TARBP2 overexpression and reduced APP and/or ZNF395 expression. Patients with tumors with higher TARBP2 or APP expression had unfavorable prognoses. Although reduced ZNF395 expression was significantly related to reduced lymph node metastasis, further studies are needed to clarify the role of TARBP2/APP/ZNF395 in breast cancer